Protalix BioTherapeutics, Inc. develops, manufactures and commercializes recombinant therapeutic proteins for rare diseases using its proprietary plant cell-based expression system, ProCellEx®. The company’s recurring news includes financial results, business updates, regulatory developments for Elfabrio® in Fabry disease, and commercial or partnership activity tied to approved enzyme replacement therapies.
Company updates also cover pipeline programs such as PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, and PRX-119, a long-acting DNase I program associated with rare kidney disease research. Protalix also reports on collaborations involving RNA-based therapeutic discovery and on its licensed relationship with Pfizer for taliglucerase alfa, Elelyso®, for Gaucher disease outside Protalix-retained rights in Brazil.
Protalix BioTherapeutics (PLX)/b) will participate in two investor conferences in New York City in mid-September 2026.Senior Vice President and Chief Financial Officer Gilad Mamlok is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, with the company presentation set for Monday, September 14, 2026 at 2:00 p.m. EDT. He will also join a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, also running September 14-16, 2026, on Wednesday, September 16, 2026 at 1:05 p.m. EDT.
A live audio webcast and archived replay of the Morgan Stanley fireside chat will be accessible via a provided webcast link and through the Events Calendar in the Investors section of the Protalix website.
Protalix BioTherapeutics (NYSE American: PLX) reported strong second quarter and year-to-date 2026 results, with revenues from selling goods rising to $19.8 million in Q2 2026 from $15.4 million a year earlier. Year-to-date total revenue reached $53.6 million versus $25.8 million, including a previously received $25.0 million milestone payment from Chiesi.
Net income was $3.8 million for Q2 2026 and $22.1 million for the first half, compared with a year-to-date net loss of $3.5 million in 2025. Cash, cash equivalents, and short-term deposits totaled $40.7 million at June 30, 2026, and the company reported no outstanding debt or warrants. Protalix reaffirmed 2026 total revenue guidance of $78.0–$83.0 million, including the Chiesi milestone, and product revenue guidance for Elfabrio and Elelyso. Operationally, the company secured a five-year U.S. patent term extension for Elfabrio, new U.S. patent protection for PRX‑115, continued enrollment in the PRX‑115 Phase 2 RELEASE trial, and advanced its PRX‑119 rare renal program.
Protalix BioTherapeutics (NYSE American: PLX) will release its second quarter 2026 financial results and provide a business update on Wednesday, August 12, 2026. Management will host a conference call and live webcast at 8:00 a.m. Eastern Daylight Time to review financial, corporate, and regulatory developments.
Investors can join via toll-free, international, or Israeli dial-in numbers using Conference ID 13761985, or through a webcast accessible from the company’s investor relations events page. A replay will be available for two weeks on the company’s website.
Protalix BioTherapeutics (NYSE American: PLX) reported Q1 2026 results and reaffirmed 2026 revenue guidance of $78–$83 million, including a $25 million Elfabrio milestone from Chiesi.
Q1 2026 revenue included $7.4 million from product sales and $26.3 million from license/R&D, driving net income of $18.3 million. Cash and deposits were $51.1 million with no debt. Elfabrio’s EU E4W dosing is approved, and the PRX‑115 Phase 2 RELEASE trial continues, with top‑line data expected in H2 2027.
Protalix BioTherapeutics (NYSE American: PLX) will release first quarter 2026 financial results and provide a business update on May 13, 2026. Management will host a conference call and live webcast at 8:00 a.m. EDT, with replay available for two weeks on the company investor website.
Investors should register 15 minutes early; call and webcast access details and Conference ID 13760475 are provided.
Protalix (NYSE:PLX) reported fiscal 2025 results and business updates on March 18, 2026. Key developments include EC approval of a 2mg/kg every‑4‑weeks (E4W) Elfabrio dosing regimen for adults with Fabry disease, triggering a $25.0 million milestone from Chiesi and supporting an expected $50.0 million cash balance by April 2026.
Management expects 2026 revenue of $78.0–$83.0 million (including the milestone), announced active enrollment in the Phase 2 PRX‑115 gout trial, and highlighted focus on rare renal programs and partnerships.
Protalix BioTherapeutics (NYSE American: PLX) will release its fiscal year 2025 financial results and provide a business update on March 18, 2026. Management will host a conference call and live webcast at 8:00 a.m. EDT to discuss results and recent corporate and regulatory developments.
Call-in numbers, webcast links, conference ID, and replay availability for two weeks on the company's investor events page are provided for investors and analysts.
Protalix (NYSE: PLX) provided a stockholder update outlining 2026 priorities: commercial execution through partners, advancement of PRX-115 for uncontrolled gout, and a focused renal pipeline including PRX-119 and an RNA collaboration with Secarna.
Key facts: Phase 1 PRX-115 showed rapid, durable urate lowering to 6 mg/dL with effects lasting up to at higher doses and generally mild tolerability; an IND for Phase 2 became effective and sites are activated. Commercially, Elfabrio launch metrics track to plan via Chiesi and Elelyso sales continue via Pfizer and Fiocruz. A CHMP negative opinion on a 2 mg/kg E4W Elfabrio regimen is under appeal with an outcome expected in Q1 2026.
Protalix (NYSE American: PLX) and Secarna Pharmaceuticals announced a collaboration and option agreement to discover antisense oligonucleotide (ASO) therapies targeting multiple rare renal indications.
Protalix selected biological targets and Secarna will use its OligoCreator® AI platform to design and profile ASO candidates, with the partners aiming to advance programs from preclinical stages toward clinical trials. Secarna grants Protalix an exclusive option for a worldwide, milestone- and royalty-bearing license to develop, market, and commercialize any active compounds from the research.
Protalix BioTherapeutics (NYSE: PLX) reported third-quarter 2025 results and a business update on November 13, 2025. YTD revenue was $43.6 million, up 24% year-over-year; Q3 revenue was $17.9 million, down 1% year-over-year. Q3 net income was ~$2.4 million ($0.03/share); YTD net loss was ~$1.1 million ($0.01/share).
R&D spending rose substantially as the company prepares a phase 2 trial of PRX-115; the company submitted an IND in October 2025 that became effective after the FDA 30-day review. A CHMP negative opinion on an Elfabrio dosing variation led to a re-examination request by Chiesi; the approved 1 mg/kg E2W Elfabrio regimen remains unchanged. Cash and equivalents were $29.4 million, stated sufficient for at least 12 months from the quarterly report date.